Shots:

• Roche highlights data from three P-III studies across the Tecentriq (atezolizumab) TNBC programme- CNS efficacy data from integrated analyses of the pivotal Rozlytrek (entrectinib) clinical development program- and the data from the registrational P-I/II ARROW trial assessing Gavreto (pralsetinib) for RET-mutant MTC patients
• Data from the P-III IPATential150 study in mCRPC patients and whose tumors had PTEN loss will also be presented
• Roche will be hosting a live roundtable discussion focusing on COVID-19 and the impact it may have on the outcomes for cancer patients. The discussion will focus on potential solutions and the lessons have been learned from the pandemic so far

­ Ref: Roche | Image: Roche